Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme
MU Schuhmann, HD Zucht, R Nassimi, G Heine… - European Journal of …, 2010 - Elsevier
AIMS: To apply modern mass spectrometry based technology to identify possible CSF
peptide markers of glioblastoma multiforme (GBM). METHODS: Mass spectrometry based
peptidomics® technology enables a systematic and comprehensive screening of
cerebrospinal fluid (CSF) with regard to its peptide composition. Differential Peptide
Display®(DPD) allows the identification of single marker peptides for a target disease. Using
both, we analyzed CSF samples of 11 patients harbouring a glioblastoma multiforme in …
peptide markers of glioblastoma multiforme (GBM). METHODS: Mass spectrometry based
peptidomics® technology enables a systematic and comprehensive screening of
cerebrospinal fluid (CSF) with regard to its peptide composition. Differential Peptide
Display®(DPD) allows the identification of single marker peptides for a target disease. Using
both, we analyzed CSF samples of 11 patients harbouring a glioblastoma multiforme in …